Clinical Trial

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

Study acronym: NUMANTIA-2
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase II, open label, randomized multicenter study to evaluate efficacy and safety of study treatment in previously untreated patients with advanced pancreatic cancer. Patients will receive study treatment for a maximum of 24 months or until progression disease or until unacceptable toxicity. In the experimental arm, patients who discontinue chemotherapy for reasons other than disease progression may continue receiving the remaining study drugs (NLM-001, botensilimab and balstilimab) up to a maximum of 24 months, according to schedule.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-05.
Trial Details
NCT Number NCT07578337
Lead Sponsor Nelum Corp
Collaborators: Apices Soluciones S.L., PH Research, S.L.
Conditions Untreated, Advanced Pancreatic Cancer
Enrollment 40 participants
Start Date 2026-07-15
Primary Completion 2029-02-28 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-13